Human Trials Tracker - Starting April 2026
Newly registered or updated clinical trials in aging and longevity research.
| Trial ID |
Intervention |
Condition |
Phase |
Status |
| NCT06630286 / NCT06630299 |
Islatravir/Lenacapavir (once‑weekly oral) – ISLEND‑1 & ISLEND‑2 |
HIV‑1 (virologically suppressed) |
III |
Completed – positive topline (June 2026) |
| NCT06313360 * |
OSK therapy (partial reprogramming) Press Release -> |
Glaucoma / NAION |
I |
First patient dosed (May 28, 2026) |
| NCT06836609 |
ALN-CIDEB (RNAi) |
MASLD / MASH (fatty liver disease) |
I |
Recruiting |
* The OSK trial (NCT06313360) has no current public record on ClinicalTrials.gov. However, the trial is actively enrolling, and the first patient was dosed on May 28, 2026. Source: Life Biosciences press release ->
Updated monthly. Source: ClinicalTrials.gov. Subscribe for monthly digest.